Kanetake H, Igawa T, Sakai H, Saito Y
Department of Urology, Nagasaki University School of Medicine.
Nihon Rinsho. 1998 Aug;56(8):2173-6.
The 5 year cancer specific survival rate of advanced prostate cancer, especially in metastatic cancer is less than 40%. Recently, maximum androgen blockade showed some beneficial effects in cases of minor disease but no additional usefulness in major cases. The treatment modality referred to as initial chemoendocrine, used to treat prostate cancer, seems to be a reasonable method because prostate cancer cells contain heterogeneity. This procedure means that the endocrine treatment is best suited to treat hormone sensitive cells, whereas chemotherapy is more appropriately used as a firstline therapy for hormone insensitive cells. We reported that the initial chemoendocrine method showed superiority in the 5 year cancer specific survival category than in the endocrine therapy analyzing non-randomized trials. From that stage on we reviewed the beneficial point of the treatment, and are now trying randomized control studies.
晚期前列腺癌，尤其是转移性癌症的5年癌症特异性生存率低于40%。最近，最大限度雄激素阻断在轻症病例中显示出一些有益效果，但在重症病例中并无额外益处。用于治疗前列腺癌的初始化学内分泌治疗模式似乎是一种合理的方法，因为前列腺癌细胞具有异质性。该程序意味着内分泌治疗最适合治疗激素敏感细胞，而化疗更适合作为激素不敏感细胞的一线治疗。我们报告称，在分析非随机试验时，初始化学内分泌方法在5年癌症特异性生存率方面比内分泌治疗更具优势。从那个阶段起，我们回顾了该治疗的有益之处，目前正在尝试进行随机对照研究。
